a nonsignificant trendp = 0.1
PFS showed a nonsignificant trend favoring the MSAF-low group (median PFS, 4.5 vs 8.0 months; p = 0.1).
PFS showed a nonsignificant trend favoring the MSAF-low group (median PFS, 4.5 vs 8.0 months; p = 0.1).
Treatment with immunotherapy-containing regimens showed a borderline association with better OS (HR, 0.40; 95% CI: 0.16–1.02, p = 0.054), although this did not reach statistical significance.